Table 1.

Socio-demographic and clinical characteristics by AT(N) biomarker profiles (n = 129)

	A+ T– (N)– (n = 58, 45%)	A+ T+ (N)– (n = 12, 9%)	A+ T– (N)+ (n = 17, 13%)	A+ T+ (N)+ (n = 42, 33%)	p value
Variable	n/%	n/%	n/%	n/%
Female sex	34/59%	10/83%	14/82%	30/71%	0.139
Carrier of the APOE ε4 allele	41/71%	8/67%	10/59%	34/81%	0.340
Type of ChEI agent					0.445
Donepezil (n = 71)	37/64%	8/67%	7/41%	19/45%
Rivastigmine (n = 24)	9/15%	1/8%	4/24%	10/24%
Galantamine (n = 34)	12/21%	3/25%	6/35%	13/31%
Variable	Mean ± standard deviation				p value
Estimated age at onset, years	72.9 ± 7.2	74.5 ± 4.8	77.1 ± 5.7	70.3 ± 6.2	0.003
Estimated duration of AD at baseline, years	3.2 ± 2.4	2.3 ± 1.4	2.2 ± 1.3	3.0 ± 1.9	0.228
Age at baseline, years	76.1 ± 6.2	76.8 ± 4.6	79.2 ± 6.2	73.3 ± 6.0	0.005
Education, years	10.2 ± 3.1	9.4 ± 1.9	9.1 ± 2.0	9.0 ± 2.0	0.116
MMSE score at baseline	21.7 ± 3.8	19.5 ± 3.7	20.6 ± 4.6	20.2 ± 4.0	0.181
ADAS-cog score (0–70) at baseline	20.8 ± 9.1	21.8 ± 9.9	20.6 ± 10.2	23.2 ± 9.3	0.633
IADL score at baseline	17.2 ± 5.7	14.6 ± 5.9	15.9 ± 5.7	15.9 ± 4.9	0.403
PSMS score at baseline	7.9 ± 2.9	7.2 ± 1.9	8.3 ± 3.1	7.4 ± 2.2	0.568
Number of concomitant medications at baseline	3.5 ± 2.8	3.3 ± 3.6	3.5 ± 2.8	2.6 ± 2.1	0.335
Aβ42, ng/ml	122 ± 22	116 ± 12	118 ± 19	115 ± 14	0.274
T-tau, ng/ml	72 ± 15	82 ± 11	122 ± 19	155 ± 46	< 0.001
P-tau, ng/ml	30 ± 13	61 ± 8	40 ± 9	79 ± 24	< 0.001

Abbreviations: A+ abnormal CSF Aβ₄₂; Aβ₄₂ amyloid-β_1–42; AD Alzheimer’s disease; ADAS-cog Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE, apolipoprotein E; ChEI cholinesterase inhibitor; IADL Instrumental Activities of Daily Living scale; MMSE Mini-Mental State Examination; (N)– normal CSF T-tau; (N)+ abnormal CSF T-tau; PSMS Physical Self-Maintenance Scale; P-tau phosphorylated tau; T– normal CSF P-tau; T+ abnormal CSF P-tau; T-tau total tau